{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:25:37Z","timestamp":1789079137922,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ctrv.2026.103174","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:22:11Z","timestamp":1782318131000},"page":"103174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Beyond body surface area: CT-derived body composition as a predictor of chemotherapy toxicity and survival in pancreatic ductal adenocarcinoma: a systematic review"],"prefix":"10.1016","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5917-9761","authenticated-orcid":false,"given":"Beatriz","family":"Chac\u00f3n-Ovejero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilma","family":"Pacheco-Barcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Palka-Kotlowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Custodio-Cabello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Guerra-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Jimenez-Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Mu\u00f1oz-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Francisco","family":"G\u00f3mez-Cerezo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3468-3626","authenticated-orcid":false,"given":"Luis","family":"Cabez\u00f3n-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ctrv.2026.103174_bb0005","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic Cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103174_bb0010","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103174_bb0015","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103174_bb0020","first-page":"853","article-title":"The use of body surface area as a criterion of drug dosage in cancer chemotherapy","volume":"18","author":"Pinkel","year":"1958","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103174_bb0025","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","article-title":"Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity","volume":"13","author":"Prado","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103174_bb0030","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)","volume":"11","author":"Sparreboom","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103174_bb0035","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103174_bb0040","doi-asserted-by":"crossref","unstructured":"Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia Nat Rev Dis Primers 2018;4:17105. doi:https:\/\/doi.org\/10.1038\/nrdp.2017.105.","DOI":"10.1038\/nrdp.2017.105"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103174_bb0045","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103174_bb0050","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3390\/cancers17040607","article-title":"Computed tomography-based sarcopenia and pancreatic Cancer survival-a comprehensive Meta-analysis exploring the influence of definition criteria, prevalence, and treatment intention","volume":"17","author":"L\u00e1inez Ramos-Bossini","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103174_bb0055","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.acra.2022.10.025","article-title":"Sarcopenia is an independent prognostic factor in patients with pancreatic Cancer - a Meta-analysis","volume":"30","author":"Thormann","year":"2023","journal-title":"Acad Radiol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103174_bb0060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000524575","article-title":"Measurement of body composition in pancreatic Cancer: a systematic review, Meta-analysis, and recommendations for future study design","volume":"39","author":"Griffin","year":"2022","journal-title":"Dig Surg"},{"key":"10.1016\/j.ctrv.2026.103174_bb0065","doi-asserted-by":"crossref","unstructured":"Cheng E, Kirley J, Cespedes Feliciano EM, Caan BJ. Adiposity and cancer survival: a systematic review and meta-analysis. Cancer Causes Control 2022 33(10):1219\u20131246.","DOI":"10.1007\/s10552-022-01613-7"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103174_bb0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3148\/74.2.2013.69","article-title":"Sarcopenia and physical function in overweight patients with advanced cancer","volume":"74","author":"Prado","year":"2013","journal-title":"Can J Diet Pract Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103174_bb0075","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12885-020-07753-w","article-title":"Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study","volume":"21","author":"Kim","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103174_bb0080","doi-asserted-by":"crossref","unstructured":"Surov A, Pech M, Gessner D, Mikusko M, Fischer T, Alter M, Wienke A. Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis Clin Nutr 2021 40(10):5298\u20135310.","DOI":"10.1016\/j.clnu.2021.08.023"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103174_bb0085","doi-asserted-by":"crossref","first-page":"6426","DOI":"10.1007\/s00330-023-09524-0","article-title":"Low skeletal muscle mass predicts treatment response in oncology: a meta-analysis","volume":"33","author":"Surov","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ctrv.2026.103174_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.102839","article-title":"Myosteatosis and prognosis in cancer: systematic review and meta-analysis","volume":"145","author":"Aleixo","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2026.103174_bb0095","doi-asserted-by":"crossref","unstructured":"Zhang X, Wei L, Li J, Deng Y, Xu W, Chen D, Li X. Influence of myosteatosis on survival of patients with pancreatic cancer: A systematic review and meta-analysis. iScience. 2024 Nov 7;27(12):111343.","DOI":"10.1016\/j.isci.2024.111343"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103174_bb0100","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1139\/H08-075","article-title":"A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care","volume":"33","author":"Mourtzakis","year":"2008","journal-title":"Appl Physiol Nutr Metab"},{"key":"10.1016\/j.ctrv.2026.103174_bb0105","doi-asserted-by":"crossref","unstructured":"Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985). 2004;97(6):2333\u20138. doi:https:\/\/doi.org\/10.1152\/japplphysiol.00744.2004.","DOI":"10.1152\/japplphysiol.00744.2004"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103174_bb0110","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.acra.2019.03.011","article-title":"A machine learning algorithm to estimate sarcopenia on abdominal CT","volume":"27","author":"Burns","year":"2020","journal-title":"Acad Radiol"},{"key":"10.1016\/j.ctrv.2026.103174_bb0115","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi:https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103174_bb0120","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","article-title":"Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index","volume":"31","author":"Martin","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103174_bb0125","doi-asserted-by":"crossref","unstructured":"Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009;15(8):2920\u20136. doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2242.","DOI":"10.1158\/1078-0432.CCR-08-2242"},{"key":"10.1016\/j.ctrv.2026.103174_bb0130","doi-asserted-by":"crossref","unstructured":"Takeda T, Sasaki T, Mie T, Furukawa T, Yamada Y, Kasuga A, et al. The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer. Jpn J Clin Oncol 2021;51(4):604\u2013611. doi:https:\/\/doi.org\/10.1093\/jjco\/hyab007.","DOI":"10.1093\/jjco\/hyaa247"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103174_bb0135","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1016\/j.clnu.2021.06.026","article-title":"An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel","volume":"40","author":"Youn","year":"2021","journal-title":"Clin Nutr"},{"key":"10.1016\/j.ctrv.2026.103174_bb0140","doi-asserted-by":"crossref","unstructured":"Cefal\u00ec M, Scala I, Pavone G, Helbling D, Hussung S, Fritsch R, et al. Is computed-tomography-based body composition a reliable predictor of chemotherapy-related toxicity in pancreatic Cancer patients? Cancers (Basel) 2023;15(17):4398. doi:https:\/\/doi.org\/10.3390\/cancers15174398.","DOI":"10.3390\/cancers15174398"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103174_bb0145","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1017\/S0007114520003463","article-title":"The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy","volume":"125","author":"Uemura","year":"2021","journal-title":"Br J Nutr"},{"key":"10.1016\/j.ctrv.2026.103174_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.878472","article-title":"Impact of baseline muscle mass and Myosteatosis on the development of early toxicity during first-line chemotherapy in patients with initially metastatic pancreatic Cancer","volume":"12","author":"Hong","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2026.103174_bb0155","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.clnesp.2024.11.004","article-title":"Skeletal muscle is independently associated with grade 3-4 toxicity in advanced stage pancreatic ductal adenocarcinoma patients receiving chemotherapy","volume":"65","author":"Aberle","year":"2025","journal-title":"Clin Nutr ESPEN"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103174_bb0160","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1590\/s0004-2803.202000000-52","article-title":"Body composition impact on survival and toxicity of treatment in pancreatic cancer: cross-sectional pilot study","volume":"57","author":"Barr\u00e8re","year":"2020","journal-title":"Arq Gastroenterol"},{"key":"10.1016\/j.ctrv.2026.103174_bb0165","first-page":"38S198","article-title":"MON-PO377: are body composition parameters associated with the clinical outcome of patients with advanced pancreatic Cancer receiving fluoropyrimidine-based chemotherapy?","author":"Som","year":"2019","journal-title":"Clin Nutr"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103174_bb0170","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41430-025-01566-5","article-title":"Impact of low muscle mass and myosteatosis on treatment toxicity and survival outcomes in non-resectable pancreatic cancer patients treated with chemoradiotherapy","volume":"79","author":"Perrier","year":"2025","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.ctrv.2026.103174_bb0175","unstructured":"Takahashi T, Mori R, Matsuyama R, Hiratani S, Yabushita Y, Sawada Y, Ohta Y, Kumamoto T, Endo I. Significance of skeletal muscle mass in neoadjuvant chemotherapy for pancreatic cancer. J Hepato-Biliary-Pancreatic Sci 2017;24(Suppl 1):A271. [Conference abstract]."},{"issue":"4","key":"10.1016\/j.ctrv.2026.103174_bb0180","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1080\/01635581.2018.1542011","article-title":"Body composition adjusted dosing of gemcitabine-nab-paclitaxel in pancreatic Cancer does not predict toxicity compared to body surface area dosing","volume":"71","author":"Freckelton","year":"2019","journal-title":"Nutr Cancer"},{"issue":"4 Suppl 1","key":"10.1016\/j.ctrv.2026.103174_bb0185","article-title":"The relationship between dose to skeletal muscle area ratio and gemcitabine nab-paclitaxel toxicity in pancreatic ductal adenocarcinoma","volume":"36","author":"Wong","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103174_bb0190","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.3390\/cancers15174368","article-title":"Muscle and adipose wasting despite disease control: unaddressed side effects of palliative chemotherapy for pancreatic Cancer","volume":"15","author":"Klassen","year":"2023","journal-title":"Cancers (Basel)."},{"issue":"10","key":"10.1016\/j.ctrv.2026.103174_bb0195","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.21873\/anticanres.17286","article-title":"Loss of skeletal muscle mass during neoadjuvant chemotherapy for pancreatic Cancer is related to the continuation of S-1 adjuvant chemotherapy after pancreatectomy","volume":"44","author":"Kawahara","year":"2024","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2026.103174_bb0200","article-title":"Body composition as a predictor of chemotherapy-related toxicity in pancreatic cancer patients: a systematic review","volume":"12","author":"Rizzo","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103174_bb0205","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/ans.70380","article-title":"The association between body composition and chemotherapy-induced toxicity in pancreatic Cancer: a systematic review","volume":"96","author":"Morgan Schlicht","year":"2026","journal-title":"ANZ J Surg"},{"issue":"13","key":"10.1016\/j.ctrv.2026.103174_bb0210","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1245\/s10434-011-1976-9","article-title":"Sarcopenia as a prognostic factor among patients with stage III melanoma","volume":"18","author":"Sabel","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103174_bb0215","doi-asserted-by":"crossref","unstructured":"van Dijk DP, Bakens MJ, Coolsen MM, Rensen SS, van Dam RM, Bours MJ, et al. Low skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer. J Cachexia Sarcopenia Muscle 2017;8(2):317\u2013326. doi:https:\/\/doi.org\/10.1002\/jcsm.12155.","DOI":"10.1002\/jcsm.12155"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103174_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.70006","article-title":"Integrating body composition and nutritional indices: a novel prognostic tool for survival in pancreatic Cancer","volume":"16","author":"Xu","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:44:19Z","timestamp":1784040259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":44,"alternative-id":["S0305737226000885"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103174","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond body surface area: CT-derived body composition as a predictor of chemotherapy toxicity and survival in pancreatic ductal adenocarcinoma: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103174"}}